Scribe Therapeutics

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

The @nytimes covers these recommendations and the importance of long-term risk reduction: nytimes.com/2026/03/13/hea… At Scribe, we are developing STX-1150, a #CRISPR epigenetic silencing therapy designed to durably lower LDL-C by repressing PCSK9 without permanent genetic changes.

❤️‍🩹 New guideline from @ACCinTouch, @American_Heart, and other leading medical organizations reflects a key shift in cardiovascular care: → Earlier LDL-C testing → Targeting lower LDL-C levels based on risk → Greater focus on prevention over time More in our thread 👇

Celebrate #WomensHistoryMonth this Thursday with a powerhouse panel of C-suite leaders, including our Chief Business Officer Svetlana Lucas. Get your ticket to the @biopioneers event for insights on the future of biotech: luma.com/583ce9z8 #WomenInSTEM #WomenInScience

Great to welcome scientists from Amgen, Grifols, and Scribe Therapeutics to the @UCBerkeley MCB Industrial Affiliates Program symposium. Industry partners met with MCB grad students & postdocs, building bridges between academia and biotech innovation.

Scribe was created to expand #CRISPR's use beyond rare diseases, said @BenjaminLOakes, co-founder and CEO, in an interview with Precision Medicine Online. Read about our progress in bringing our lead therapy for cardiovascular disease to the clinic 👉 precisionmedicineonline.com/business-news/…

Join us at today's @KeystoneSymp Precision Genome Engineering conference, where we're presenting our latest #EpigeneticEditing advances at 7:30pm. 📣 ADDing a Lock to Epigenome Editing: DNMT3A Allostery Enhances Specificity and Potency of #CRISPR-CasX-based Epigenetic Repressors

For this International @womensday, our Scribe team came together to assemble care packages for women and communities in need. Thank you to everyone who showed up to #GiveToGain in support of women everywhere. #InternationalWomensDay #WomenInSTEM

Interested in a deeper dive into the science and engineering behind STX-1150 and our ELXR epigenetic silencing tech? Check out @BioWorld’s feature on the scientific highlights for in vivo genetic medicine in 2025. bioworld.com/articles/72745…

Hypercholesterolemia is a major driver of cardiovascular disease. This @BioWorld article covers our work to advance STX-1150 – designed to durably lower LDL-C via epigenetic silencing of PCSK9 – into the clinic and meaningfully change how #CVD is treated. bioworld.com/articles/72818…

Read the latest in @LongevityTech about our second success milestone with @EliLillyandCo and the demonstration of “steady, disciplined progress toward a future where genetic medicine plays a central role in how we manage aging and chronic disease." longevity.technology/news/gene-edit…

In @CardioBusiness, @DaveFornell covers: ➡️ Our lead therapy STX-1150, designed to address the gap in treatment efficacy ➡️ Preclinical NHP data showing >50% LDL-C reduction maintained for ~18 months ➡️ Phase 1 study expected in mid-2026 cardiovascularbusiness.com/topics/clinica…

At Scribe, we believe the standard of cardiovascular care today needs a paradigm shift. @CardioBusiness spotlights our development of novel #CRISPR-based medicines that target the key lipid drivers of ASCVD – check out the article preview and link below. 👇

Read the @Forbes daily cover story on Dr. Doudna: forbes.com/sites/amyfeldm… And a 2023 feature on Scribe: forbes.com/sites/alexknap… #CRISPR #GeneEditing #GeneticMedicine

Dr. Jennifer Doudna, Nobel laureate & Scribe co-founder, is one of America’s greatest innovators. Our CEO and co-founder @BenjaminLOakes spoke with @Forbes about her unmatched impact on science and medicine. Check out Dr. Doudna’s Forbes 250 profile in the links below 👇

We believe that purpose-built #CRISPR technologies can reach the potency & specificity needed for transformative medicines. And this is the engineering philosophy we are applying in parallel across our wholly owned cardiometabolic pipeline. Read more 👇 businesswire.com/news/home/2026…

We achieved a second success milestone with @EliLillyandCo in our collaboration to advance in vivo #CRISPR-based therapies for neurological and neuromuscular disorders. Progress like this matters because patients cannot wait. More details in thread 🧵 #CRISPR #GeneEditing

Read the @BiopharmaTrend article: biopharmatrend.com/news/scribe-to… Dive deeper into the science with our preprint: biorxiv.org/content/10.648… @biorxivpreprint #CRISPR #Epigenetics #EpigeneticEditing

Our thanks to @BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer. The result: Improved precision for CRISPR-based therapeutics. Details⬇️

Read more about our approach to improving cardiovascular health and longevity in this @LongevityTech piece by @mrdannysullivan: longevity.technology/news/epigeneti… #HeartDisease #OurHearts #HeartMonth

Can #CRISPR genetic medicine solve cardiovascular disease? We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @LongevityTech article below 👇